title: Treatment of interdigital tinea pedis with a 4-week once-daily regimen of butenafine hydrochloride 1% cream.
abstract: BACKGROUND
  Butenafine hydrochloride, a potent new benzylamine with fungicidal activity, has been extensively studied and approved for topical use in Japan. Results reported here are from one of the first major North American butenafine clinical trials.
  
  
  OBJECTIVE
  We evaluated butenafine in the treatment of tinea pedis in a controlled, randomized, double-blind trial.
  
  
  METHODS
  Of 80 patients with positive fungal cultures, 40 applied butenafine 1% cream and 40 applied vehicle to the affected area once daily for 4 weeks. Efficacy was assessed during treatment and 4 weeks after.
  
  
  RESULTS
  Significantly more patients using butenafine than using vehicle had mycologic cure (butenafine, 88%; vehicle, 33%) and effective clinical response (butenafine, 78%; vehicle, 35%). Differences between treatment groups were greatest (p < 0.001) 4 weeks after treatment.
  
  
  CONCLUSIONS
  Butenafine applied once daily for 4 weeks resulted in an effective clinical response and mycologic cure of tinea pedis during treatment. Patients continued to improve for at least 4 weeks after treatment.
authors.affiliation: Department of Dermatology, University of New Mexico School of Medicine, Albuquerque, USA.
authors.forename: E
authors.initials: E
authors.lastname: Tschen
authors.forename: B
authors.initials: B
authors.lastname: Elewski
authors.forename: D C
authors.initials: DC
authors.lastname: Gorsulowsky
authors.forename: D M
authors.initials: DM
authors.lastname: Pariser
mesh_terms: D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001596:Benzylamines / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000008:administration & dosage* / Q000009:adverse effects; D011537:Pruritus / Q000139:chemically induced; D012074:Remission Induction; D014008:Tinea Pedis / Q000188:drug therapy*; D014249:Trichophyton / Q000302:isolation & purification
chemical_list: D000935:Antifungal Agents; D001596:Benzylamines; D009281:Naphthalenes; C067594:butenafine